BioCryst Pharmaceuticals, Inc. enters into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO®(berotralstat) in the pan-Latin America (LATAM) region.
“We are pleased to join forces with Pint Pharma to bring our oral, once-daily therapy to HAE patients in LATAM who are in need of a new treatment option. Pint Pharma is the ideal partner for BioCryst based on the team’s deep experience in rare diseases that spans multiple aspects of commercialization and their established network across this important region,” says Charlie Gayer, CEO of BioCryst.
“Our partnership with BioCryst is significant for Pint Pharma given the critical unmet need among HAE patients in LATAM who are seeking an innovative treatment option for this serious disease. ORLADEYO has successfully launched in multiple markets across the globe, and we are privileged to leverage our expertise to support BioCryst in introducing this prophylactic therapy to the region,” says David Munoz, CEO and co-founder of Pint Pharma.
Under the terms of the agreement, Pint Pharma will be responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the pan-LATAM region.
Pint Pharma is an Austria-based pharmaceutical company that has extensive experience developing, registering and commercializing rare disease and specialty treatments throughout Latin America and Europe.
(Source: BioCryst)
